Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT03410108 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
104
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Takeda